BRPI0821450A2 - Derivado (aza) indol substituído na posição 5, proceso para a preparação do mesmo, composto intermediário, e, composição farmacêutica. - Google Patents

Derivado (aza) indol substituído na posição 5, proceso para a preparação do mesmo, composto intermediário, e, composição farmacêutica.

Info

Publication number
BRPI0821450A2
BRPI0821450A2 BRPI0821450-6A BRPI0821450A BRPI0821450A2 BR PI0821450 A2 BRPI0821450 A2 BR PI0821450A2 BR PI0821450 A BRPI0821450 A BR PI0821450A BR PI0821450 A2 BRPI0821450 A2 BR PI0821450A2
Authority
BR
Brazil
Prior art keywords
aza
substituted
preparation
pharmaceutical composition
intermediate compound
Prior art date
Application number
BRPI0821450-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Maria Alessandra Alisi
Guido Furlotti
Nicola Cazzolla
Caterina Maugeri
Patrizia Dragone
Barbara Garofalo
Isabela Coletta
Giorgina Magano
Beatrice Garrone
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of BRPI0821450A2 publication Critical patent/BRPI0821450A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
BRPI0821450-6A 2007-12-28 2008-12-16 Derivado (aza) indol substituído na posição 5, proceso para a preparação do mesmo, composto intermediário, e, composição farmacêutica. BRPI0821450A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07425830A EP2078711A1 (en) 2007-12-28 2007-12-28 (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor
PCT/EP2008/067622 WO2009083436A1 (en) 2007-12-28 2008-12-16 (aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor

Publications (1)

Publication Number Publication Date
BRPI0821450A2 true BRPI0821450A2 (pt) 2015-06-16

Family

ID=39167787

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821450-6A BRPI0821450A2 (pt) 2007-12-28 2008-12-16 Derivado (aza) indol substituído na posição 5, proceso para a preparação do mesmo, composto intermediário, e, composição farmacêutica.

Country Status (20)

Country Link
US (2) US8399477B2 (https=)
EP (3) EP2078711A1 (https=)
JP (1) JP5698985B2 (https=)
KR (2) KR101671874B1 (https=)
CN (1) CN101910127B (https=)
AR (1) AR069961A1 (https=)
AU (1) AU2008342705B2 (https=)
BR (1) BRPI0821450A2 (https=)
CA (1) CA2707339C (https=)
DK (2) DK2234968T3 (https=)
EA (1) EA020373B1 (https=)
ES (2) ES2523167T3 (https=)
GE (1) GEP20125547B (https=)
IL (1) IL206062A (https=)
PL (2) PL2444392T3 (https=)
PT (2) PT2234968E (https=)
SG (1) SG187400A1 (https=)
SI (2) SI2234968T1 (https=)
UA (1) UA100867C2 (https=)
WO (1) WO2009083436A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101365824B1 (ko) 2010-10-22 2014-02-20 엘지디스플레이 주식회사 유기전계발광소자
EP3102576B8 (en) 2014-02-03 2019-06-19 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridine inhibitors of ror-gamma
PT3133068T (pt) * 2014-04-14 2021-01-06 Shanghai hengrui pharmaceutical co ltd Derivados de amida e sais farmacêuticos destes, método de preparação destes e aplicação medicinal destes
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2017024018A1 (en) 2015-08-05 2017-02-09 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
US11008340B2 (en) 2015-11-20 2021-05-18 Vitae Pharmaceuticals, Llc Modulators of ROR-gamma
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
CN107033026A (zh) * 2017-06-07 2017-08-11 李博强 一种对硝基苯肼盐酸盐的制备方法
JP2020528904A (ja) 2017-07-24 2020-10-01 ヴァイティー ファーマシューティカルズ，エルエルシー ＲＯＲγの阻害剤
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
KR102711104B1 (ko) * 2019-08-26 2024-09-27 국제약품 주식회사 인돌 카복사미드 유도체 및 그를 포함하는 약제학적 조성물
CN114605303A (zh) * 2022-03-14 2022-06-10 武汉工程大学 一种地拉韦啶及其中间体的合成方法
CN119019389A (zh) * 2024-06-05 2024-11-26 四川大学 7-氮杂吲哚类化合物及其合成方法和用途
CN119101040B (zh) * 2024-11-08 2025-03-21 杭州澳赛诺医药技术有限公司 一种通过去对称化合成芳基取代的手性四氢吡喃环的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2354766A1 (fr) 1976-06-17 1978-01-13 Labaz Derives n-aminoalkyles d'indole et procedes pour les preparer
JP2002502844A (ja) * 1998-02-03 2002-01-29 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト ５員複素環縮合ベンゾ誘導体、その調製及び医薬品としてのそれらの使用
US6114532A (en) * 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
DE19834751A1 (de) * 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
AU2001247589A1 (en) * 2000-03-20 2001-10-03 Axys Pharmaceuticals, Inc. Non-amidine containing protease inhibitors
US20020052373A1 (en) * 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
IL140096A0 (en) * 2000-12-05 2002-02-10 Internat Specialty Products Is Process for preparation of zafirlukast
DE10147672A1 (de) * 2001-09-27 2003-04-10 Bayer Ag Substituierte 2,5-Diamidoindole und ihre Verwendung
WO2004056768A2 (en) * 2002-12-20 2004-07-08 Bayer Healthcare Ag Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
SE0300908D0 (sv) * 2003-03-31 2003-03-31 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
US7618964B2 (en) 2004-12-23 2009-11-17 Hoffmann-La Roche Inc. Benzamide derivatives, their manufacture and use as pharmaceutical agents
US20090258917A1 (en) * 2005-10-12 2009-10-15 Benjamin Pelcman Benzoxazoles Useful in the Treatment of Inflammation
EP2674428B1 (en) * 2006-04-07 2016-04-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
JP2008006663A (ja) * 2006-06-28 2008-01-17 Pilot Ink Co Ltd 出没式筆記具
ITMI20061368A1 (it) * 2006-07-14 2008-01-15 Acraf Composto 2-arilindolico sostituito in posizione 5, composizione farmaceutica che lo comprende nonche' composti intermedi e procedimento per prepararlo

Also Published As

Publication number Publication date
EA020373B1 (ru) 2014-10-30
EP2444392A1 (en) 2012-04-25
AR069961A1 (es) 2010-03-03
ES2408955T3 (es) 2013-06-24
PL2234968T3 (pl) 2013-08-30
US8399477B2 (en) 2013-03-19
US8871948B2 (en) 2014-10-28
CA2707339A1 (en) 2009-07-09
KR101671874B1 (ko) 2016-11-03
EP2234968A1 (en) 2010-10-06
CN101910127B (zh) 2013-01-23
PT2234968E (pt) 2013-06-03
DK2234968T3 (da) 2013-06-17
EA201070804A1 (ru) 2010-12-30
EP2444392B1 (en) 2014-09-24
KR20160029861A (ko) 2016-03-15
IL206062A (en) 2015-08-31
CA2707339C (en) 2018-05-01
HK1145172A1 (en) 2011-04-08
GEP20125547B (en) 2012-05-25
AU2008342705A1 (en) 2009-07-09
JP5698985B2 (ja) 2015-04-08
IL206062A0 (en) 2010-11-30
SI2234968T1 (sl) 2013-06-28
CN101910127A (zh) 2010-12-08
WO2009083436A1 (en) 2009-07-09
HK1165410A1 (en) 2012-10-05
US20130158269A1 (en) 2013-06-20
EP2078711A1 (en) 2009-07-15
EP2234968B1 (en) 2013-03-27
JP2011507929A (ja) 2011-03-10
DK2444392T3 (en) 2014-12-08
AU2008342705B2 (en) 2013-11-14
PL2444392T3 (pl) 2015-03-31
PT2444392E (pt) 2014-11-19
SG187400A1 (en) 2013-02-28
KR20100103569A (ko) 2010-09-27
UA100867C2 (uk) 2013-02-11
SI2444392T1 (sl) 2014-12-31
US20100286189A1 (en) 2010-11-11
ES2523167T3 (es) 2014-11-21

Similar Documents

Publication Publication Date Title
BRPI0821450A2 (pt) Derivado (aza) indol substituído na posição 5, proceso para a preparação do mesmo, composto intermediário, e, composição farmacêutica.
LTC2187879I2 (lt) Farmacinė kompozicija, apimanti gliukopiranozil-pakeistojo benzeno darinį
DK2206710T3 (da) Indolderivater som s1p1-receptor agonister
IL205360A0 (en) Methods, kits, and compositions for administering pharmaceutical compounds
BRPI0814958A2 (pt) Compostos de indazol ou indol, composição, e, método para preparar uma composição.
BRPI0811712A2 (pt) "composto, processo de preparação de um composto e composição farmacéutica".
BRPI0910734A2 (pt) composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo.
ZA200802007B (en) 1,3-disubstituted indole derivatives for use as PPAR modulators
ZA201001335B (en) 2,3-substituted indole derivatives for treating viral infections
CL2007003049A1 (es) Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
DE602008005634D1 (de) 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
BRPI0922566A2 (pt) polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
AP2384A (en) 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them.
IL189139A0 (en) Trazodone composition for once a day administration
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
ZA201002217B (en) 1,3-dihydroisoindole derivatives
IL188069A0 (en) Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
IL193774A0 (en) Pharmaceutical compositions containing a 3,5-seco-4-norcholestane derivative
PT2231598E (pt) Novos derivados diazéniodiolato, processo para a sua preparação e as composições farmacêuticas que os contenham
ZA200902414B (en) Indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
ZA200903829B (en) Indole derivatives as S1P1 receptor agonists
ZA200902413B (en) Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HU0500683D0 (en) New arylpiprazole salts for producing pharmaceutical composition
ATE489943T1 (de) Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivate
GB0617966D0 (en) Novel 2 amino-pyrimidine derivatives, processes for preparing them, pharmaceutical compositions thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.